Abstract
Establishing appropriate and practical methodology is a key to progress in the investigation of chemotherapy-induced nausea and vomiting. Critical issues include patient response assessment, proper trial design for evaluating new agents, and the definition of chemotherapy emetogenicity. In assessing antiemetic response, the primary end-point should be complete control of emesis and nausea. Emesis and nausea should be independently assessed with the period of observation defined (acute, delayed, anticipatory). Emesis can be evaluated by measuring the number of emetic episodes either by direct observation or by patient self-report using patient-completed diaries. Nausea should be measured by patient self-report with the standard parameters, including frequency and intensity. New antiemetic drug development should proceed in an orderly progression from open-label phase I/II trials defining tolerance and minimally fully effective dose to phase III comparative trials. A randomized, parallel, double-blind study is the preferred design for the latter, and the comparator arm should always include the current best available treatment. Antiemetic placebos are no longer acceptable with chemotherapy regimens known to produce emesis in a majority of patients. None of the emetogenic classifications proposed to date adequately accounts for all known important patient- and treatment-related prognostic variables. A modification of a recently reported schema is proposed for use in making antiemetic treatment recommendations and defining the emetogenic challenge in clinical trials.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Aapro M (1993) Methodological issues in antiemetic studies. Investigational New Drugs 11: 243–253
Beck TM, Ciociola AA, Jones SE et al (1993) Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med 118: 407–413
Clark RA, Tyson LB, Frisone M (1985) A correlation of objective and subjective parameters in assessing anti-emetic regimens. Proc Tenth Ann Cong Oncol Nurs Soc 2: 96
Craig JB, Powell BL (1987) The management of nausea and vomiting in clinical oncology (review). Am J Med Sci 34–44
Cubeddu LX, Hoffman IS, Fuenmayor NT et al (1990) Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. J Clin Oncol 8: 1721–1727
Cubeddu LX, Pendergrass K, Ryan T et al (1994) Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapy. Am J Clin Oncol 17: 137–146
D’Acquisto R, Tyson LB, Gralla RJ et al (1986) The influence of a chronic high alcohol intake on chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol 5: 257
DelFavero A, Roila F, Basurto C et al (1990) Assessment of nausea. Eur J Clin Pharmacol 38: 115
DelFavero A, Tonato M, Rolla F (1992) Issues in the measurement of nausea. Br J Cancer 66 [Suppl]: S69 - S71
DiBenedetto J Jr, Cubeddu LX, Ryan T et al (1995) Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy. Clin Ther 17: 1091–1098
Fetting JH, Grochow LB, Folstein MF et al (1982) The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 66: 1487–1493
Geddes DM, Dones L, Hill E et al (1990) Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily diary card in a randomized trial. Eur J Cancer 26: 484–492
Gralla RJ, Itri LM, Pisko SE et al (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305: 905–909
Gralla RJ, Clark RA, Kris MG et al (1991) Methodology in anti-emetic trials. Eur J Cancer 27: S5 - S8
Grunberg SM, Hesketh PJ (1993) Control of chemotherapy-induced emesis. N Engl J Med 329: 1790–1796
Haysteen H, Nielsen H, Kiaer M (1986) The use of visual analogue scale ( VAS) in patients receiving cisplatin-containing chemotherapy. Proc Am Soc Clin Oncol 5: 263
Hesketh PJ, Murphy WK, Lester EP et al (1989) GR 38032F (GR-C507175): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7: 700–705
Hesketh PJ, Plagge P, Bryson JC (1992) Single-dose ondansetron for prevention of acute cisplatin-induced emesis: analysis of efficacy and prognostic factors. In: Bianchi AL, Grelot L, Miller AD, King GL (eds) Mechanisms and control of emesis. John Libbey, London, pp 25–26
Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15: 103–109
Holmes S, Eburn E (1989) Patients’ and nurses’ perceptions of symptom distress in cancer. J Adv Nurs 14: 840–846
Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332: 1–5
Kris MG, Gralla RJ, Clark RA et al (1985) Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep 69: 1257–1262
Laszlo J (1982) Treatment of nausea and vomiting caused by cancer chemotherapy. Cancer Treat Rev 9: 3–9
Lindley CM, Bernard S, Fields SM (1989) Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population. J Clin Oncol 7: 1142–1149
Martin M, Diaz Rubio E, Sanchez A et al (1990) The natural course of emesis after carboplatin treatment. Acta Oncologica 29: 593–596
Melzack R (1989) Measurement of nausea. J Pain Symptom Manage 4: 157–160
Morrow GR (1984) The assessment of nausea and vomiting: past problems, current issues, and suggestions for future research. Cancer 53 [Suppl]: 2267–2278
Olver IN, Simon RM, Aisner J (1986) Antiemetic studies: a methodological discussion. Cancer Treat Rep 70: 555–563
Smyth JF (1988) The problem of emesis induced by cancer chemotherapy. Clinician 6: 2–12
Strum SB, McDermed JE, Pileggi J et al (1984) Intravenous metoclopramide: prevention of chemotherapy-induced nausea and vomiting. Cancer 53: 1432–1439
Tonato M, Roila F, DelFavero A (1991) Methodology of antiemetic trials: a review. Ann Oncol 2: 107–114
Tonato M, Roda F, DelFavero A (1996) Methodology of trials with antiemetics. Support Care Cancer 4: 281–286
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Hesketh, P.J., Gralla, R.J., du Bois, A., Tonato, M. (1998). Methodology of Antiemetic Trials: Response Assessment, Evaluation of New Agents, and Definition of Chemotherapy Emetogenicity. In: Gralla, R.J., Tonato, M., Roila, F. (eds) Perugia Consensus Conference on Antiemetic Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72137-3_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-72137-3_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-72139-7
Online ISBN: 978-3-642-72137-3
eBook Packages: Springer Book Archive